Introduction
Prothrombin complex concentrates (PCCs) were originally developed as a source of factor IX for the treatment of patients with haemophilia B [1] . Subse quently, PCCs were used in the treatment of bleeding in haemophilia patients with inhibitors [1] . Th ese concen trates have largely been superseded in this setting by high-purity, plasma-derived factor IX and, more recently, recombinant factor IX and bypassing agents such as activated PCC and recombinant activated factor VII.
Today, PCCs are mainly used for the emergency reversal of oral vitamin K antagonist (VKA) therapy [2, 3] , although in the USA they are only approved for haemophilia. Bleeding is the most frequent complication of oral anticoagulation, causing considerable morbidity and mortality [4] . Emergency reversal of anticoagulation is most commonly needed to control bleeding as quickly as possible. Th e use of PCCs has also been proposed in severe liver disease and in perioperative and traumarelated bleeding [5] [6] [7] [8] , although fewer studies have been performed in these settings than for anticoagulation reversal.
Most commercially available PCCs contain four vitamin K-dependent coagulation factors (II, VII, IX and X), although not all contain factor VII ( Table 1) . A recent study of PCC constituents found broad correlation with the products' labelled values [9] . In most currently available PCCs, the factors are found in the inactivated form. In addition to the coagulation factors, many of today's PCCs include one or more of the following coagulation inhibitors: heparin, antithrombin, protein C, protein S and protein Z.
In settings where rapid correction of coagulopathy is required, such as in cases of intracranial haemorrhage [10] , PCCs may off er some advantages over fresh frozen plasma (FFP), the traditionally established therapy. For reasons such as reduced volume, room-temperature storage and lack of requirement for blood type matching, the total time for administration is much reduced with PCCs compared with FFP. Furthermore, most currently available PCCs are subjected to at least one viral in activation step (Table 1) , which reduces the risk of pathogen transmission. Also, as PCCs are free of leukocytes and some are also nanofi ltrated, they are unlikely to provoke transfusion-related acute lung injury.
Historically, the major drawback of PCCs has been the risk of thrombotic complications [11] . Today's PCCs diff er considerably from the preparations used to treat Abstract Prothrombin complex concentrates (PCCs) are used mainly for emergency reversal of vitamin K antagonist therapy. Historically, the major drawback with PCCs has been the risk of thrombotic complications. The aims of the present review are to examine thrombotic complications reported with PCCs, and to compare the safety of PCCs with human fresh frozen plasma. The risk of thrombotic complications may be increased by underlying disease, high or frequent PCC dosing, and poorly balanced PCC constituents. The causes of PCC thrombogenicity remain uncertain but accumulating evidence indicates the importance of factor II (prothrombin). With the inclusion of coagulation inhibitors and other manufacturing improvements, today's PCCs may be considered safer than earlier products. PCCs may be considered preferable to fresh frozen plasma for emergency anticoagulant reversal, and this is refl ected in the latest British and American guidelines. Care should be taken to avoid excessive substitution with prothrombin, however, and accurate monitoring of patients' coagulation status may allow thrombotic risk to be reduced. The risk of a thrombotic complication due to treatment with PCCs should be weighed against the need for rapid and eff ective correction of coagulopathy. 
Literature search strategy
We used the PUBMED database to search for publications with 'complex concentrate(s)' or 'coagulation factor concentrate(s)' as key words, plus additional terms including 'anticoagulation reversal' and 'over-anticoagula tion' . Citations were selected from articles published in English between 1988 and 2010.
Thrombotic complications with PCCs
Th rombotic complications associated with PCCs include venous thromboembolism, disseminated intravascular coagulation (DIC), microvascular thrombosis and myocardial infarction [1] . An overview of studies that have reported such complications is presented in Table 2 . Th e risk of thrombotic complications occurring with PCCs or other procoagulant haemostatic interventions must be considered in the context of any underlying disease and the patient's clinical condition at the time of PCC administration [12] .
Haemophilia
Prior to the introduction of high-purity, plasma-derived factor IX, haemophilia B patients were treated with PCCs. As haemophilia B patients are defi cient in factor IX only, administration of PCC will produce supraphysiological levels of the other factors in the preparationthis, coupled with the need for repetitive dosing in haemophilia B, can increase patients' risk of thrombosis. Since the introduction of PCCs for haemo philia in the 1960s, complications such as deep vein thrombosis, DIC and pulmonary embolism have been reported. In a survey of 150 physicians in several coun tries, 72 thrombotic complications occurring between 1987 and 1990 were reported [11] . An increased risk of adverse eff ects was seen in patients with large muscle haematomas, immobilisation and orthopaedic surgery. In these conditions, treatment involves administration of large, repeated doses of PCCs [11] . In the 1980s, several cases of acute myocardial infarction in young haemo philiacs with inhibitors were reported; many of these patients had received large, repeated doses of PCCs [13] .
Anticoagulation reversal
All patients receiving VKA therapy have underlying thrombotic risk factors, which may be unmasked when anticoagulation is reversed. A review of 14 studies each [54] , excluding concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. Factor VII presented in parentheses for three-factor PCCs.
involving at least 10 patients (a total of 460 patients) in which PCCs were administered for anticoagulation reversal revealed no evidence of DIC [14] . Th ere were, however, seven thrombotic complications (that is, 1.5% of patients experienced a thrombotic event). Four of these, two deep vein thromboses and two non-ST elevation myocardial infarctions which were identifi ed in a retrospective review of 58 patients, were not attributed to PCC therapy [15] . Two throm botic strokes occurred in patients with extensive co-morbidities [16] . Th e fi rst patient, a 75-year-old male, suff ered from multi-infarct brain damage, longstanding hypertension, atrial fi bril lation and vascular disease of the legs. Th e other patient was an 86-year-old female with atrial fi brillation and a large haematoma in the left leg. Finally, a patient with peripheral vascular disease, sepsis and renal and cardiac failure died of a thrombotic stroke 48 hours after PCC treatment, following leg ampu tation [17] . Th ree further thrombotic complications associated with PCC use have been identifi ed in articles published since Leissinger and colleagues' review [14] . A study of PCC use in 43 patients requiring emergency reversal of VKA therapy was published more recently [18] . One serious adverse event, suspected pulmonary embolism leading to the death of a patient, was considered possibly related to study treatment. Th is patient had an underlying risk of thrombosis relating to metastatic gastrointestinal cancer and atrial fi brillation. In a recent case report, a patient receiving PCC for anticoagulant reversal suff ered a fatal myocardial infarction [19] . Myocardial infarction is a fre quent perioperative complication in the absence of PCC treatment and no defi nite causal link with PCC adminis tration could be established in this case. Furthermore, the patient may have had DIC related to abdominal sepsis. A second case report, published by Warren and Simon, involved a patient who received treatment with PCC and subsequently suff ered massive, fatal intracardial throm bosis [20] . Although the authors suggest this may have been a complication of PCC treatment, there were several important underlying risk factors. Th e patient had a history of ischaemic stroke and deep venous thrombosis. Th e International Normalised In all of these cases, therefore, the patients receiving PCCs had increased risk of thrombosis due to medical history or current illness. As this refl ects the usual context of PCC administration, a small number of compli cations may be expected. Th e possibility that PCC administration has some infl uence over the risk cannot be excluded. In most recent cases in the literature, however, it seems unlikely that PCC alone was the cause.
Perioperative and trauma-related bleeding
During the past decade, there have been several reports of PCC therapy for critical bleeding. Th e aim of this approach is to correct critically reduced thrombin generation, resulting from major blood loss, consumption of coagulation factors and volume administration (this excludes patients requiring anticoagulation reversal or with a procoagulant status and prophylactic use of PCCs). Although there have been few authoritative studies of PCCs in this setting, the clinical practice has been used in European countries such as Austria, Germany and Switzer land in cases with increased bleeding and prolonged initiation of coagulation as measured by viscoelastic techniques [21] . Recently published Austrian expert opinion consensus recommendations advocate administration of PCC (20 to 30 IU/kg bodyweight) in the case of persistent bleeding and prolonged clotting time [6] . Adequate substitution of fi brinogen was also recommended, prior to administration of PCC.
Regarding the possible complications associated with accelerating thrombin generation by administration of PCC in the perioperative setting, a cluster of fi ve fatal PCC-related thrombotic events in German patients under going surgery was reported in the 1990s [22] . None of these cases may be considered classical perioperative PCC use: two patients required anticoagulation reversal, two patients had procoagulant states (including sepsis, DIC or high levels of platelets and fi brinogen), and one patient received PCC prophylactically (that is, without clinical signs of bleeding). All fi ve patients were treated with an old PCC that was withdrawn from the market in 1994 as a result of three of the fatalities [22] . Compared with other PCCs available at the time, the withdrawn product had high levels of factors II and X and activated factor VII, low levels of protein S, and no free antithrombin activity, although heparin levels were relatively high [22, 23] . Co-administration of aprotinin was also identi fi ed as playing a possible role in three of the cases [22] . More recently, there have been no reports of thrombotic complications with PCCs in the treatment of perioperative or trauma-related bleeding, although only a few studies have been published in these settings [8, 24, 25] .
PCCs and thrombotic risk: pathogenesis
Th e potential causes of thrombogenic complications after PCC administration remain a subject for debate. Early studies in animal models implicated activated factor IX or the presence of procoagulant phospholipids as poten tial thrombogenic determinants in PCCs [26, 27] . A reduc tion in thromboembolic complications among haemo philia B patients was observed when highly-purifi ed factor IX began to replace PCCs. However, direct measure ment of activated factor IX revealed that there tended to be higher levels in highly-purifi ed factor IX preparations than in PCCs [28] , suggesting that levels of activated factor IX do not correlate with thrombogenicity.
An in vitro model of thrombogenicity has been used recently to systematically examine which components of PCCs contribute to thrombogenicity [29] . Zymogen overload, of prothrombin in particular, was implicated in this study as the main mechanism for the thrombogenic potential of PCCs. Other studies have also cited prothrombin as the major determinant of excessive thrombin generation in an activated PCC preparation [30] .
Th e need for balance between procoagulants and anticoagulants was suggested by a recent in vitro study of thrombin generation in blood from patients with liver cirrhosis [31] . Th e authors suggest that haemostasis is preserved in these patients because the reduction of procoagulants (factor II) is balanced by reduced levels of the coagulation inhibitor protein C.
Two studies, using diff erent methodologies, have shown that increased levels of factors VII, IX and X did not infl uence total thrombin generation [32, 33] . In contrast, there is a linear relationship between increasing levels of factor II and increased thrombin generation [32, 33] . Finally, a recently published study has shown that, following activation with a high concentration of tissue factor, prothrombin is amongst the main deter minants of total thrombin generation [34] . Th e available evidence therefore indicates that accumulation of factor II could be the primary determinant of thrombotic risk associated with frequent doses of PCC. Th e half-lives of the coagulation factors diff er considerably, with factors II and X having the longest half-lives of the factors administered in PCC (60 and 30 hours, respectively, compared with 6 hours for factor VII and 20 hours for factor IX) [35] . As a consequence, repeated dosing will lead to an accumulation of factors II and X as illustrated in Figure 1 .
Overall, there remains some uncertainty as to which component(s) of PCCs is the leading cause of thrombogenicity, but there is accumulating evidence for the impor tance of factor II and the balance between this coagulation factor and coagulation inhibitors.
Diff erences between today's PCCs and older products
Today's PCCs have improved safety compared with those used in the 1970s and 1980s [12] . Th is improvement is probably related to the inclusion of coagulation inhibitors such as heparin, antithrombin, protein C, protein S and protein Z. Th ese constituents may be speculated to provide some balance to the eff ects of the coagulation factors, the aims being to avoid excessive increase in thrombin generation and to reduce thrombotic risk. Th e inclusion of coagulation inhibitors is consistent with recommendations to administer early PCCs together with heparin and antithrombin [11] .
Th e eff ects of one currently available PCC (Beriplex P/N; CSL Behring, Marburg, Germany) have been studied in healthy volunteers (n = 15) [36] . Considerable increases in coagulation factor levels were observed, and these were accompanied by increases in plasma concentrations of proteins C and S. Importantly, there was no clinical evidence of thrombosis, and no increase in the thrombogenicity marker D-dimer [36] .
In a recent study, the biochemical composition of seven commercially available PCCs was measured. With one exception -Uman Complex (Kedrion, Castelvecchio Pascoli, Italy), which contained negligible factor VIIcoagulation factor levels were broadly similar in all seven products, and all tested negative for activated coagulation factors [9] . Th ere were, however, some diff erences in coagu lation inhibitor levels (Figure 2 ), resulting in diff er ent thrombin inhibitory capacities. Th ere were also considerable purity diff er ences between the products. It is noteworthy that all of the PCCs contained considerable concentrations of pro thrombin (factor II), and that S-TIM 4 or Prothromplex (Baxter, Vienna, Austria) had a higher factor II:factor IX ratio than the other products [9] .
Pharmacovigilance data for some of the currently available PCCs (Table 3) demonstrate that, although millions of units have been administered to thousands of patients, there have been no proven cases of infection transmission, heparin-induced thrombocytopaenia or thromboembolism.
One may question how the safety profi le of today's three-factor PCCs compares with that of the four-factor products. Unfortunately no comparator trials have been performed, so there are no defi nitive answers. Given the apparent importance of factor II in thrombotic risk, and the fact that the key diff erence between the two types of PCC is the presence or absence of factor VII, no major inherent diff erences may be expected. Th ree-factor PCCs have been reported as suboptimal for warfarin reversal, owing to the absence of factor VII [37] . Th us. it has been recommended that four-factor PCCs are probably preferable to three-factor PCCs or FFP, for acute reversal of oral VKAs [38] .
Comparing PCCs with human plasma
Th e primary alternative to PCCs -particularly for anticoagulant reversal, but also for treatment of acquired coagulopathy in the perioperative setting -is human plasma. Th rombotic complications with human plasma are rare, which could be cited as an advantage versus PCCs. However, there are major drawbacks with human plasma versus PCCs. Firstly, a considerably longer time is taken to reach haemostasis with human plasma. Before it can be administered, compatibility testing is required and the human plasma must be thawed and warmed. Th e low concentration of coagulation factors in normal human plasma means that a large volume may be required to deliver enough of the factors to achieve eff ective haemostasis. As well as the risk of volume overload, this results in an extended administration time. Hence, the time taken for preparation and administration of human plasma is typically 1 or 2 hours. In contrast, PCCs can be administered immediately and a lower volume is required; an important consideration when the rapid reversal of anticoagulant therapy may be life-saving.
Human plasma transfusion is associated with other potential adverse reactions, including transfusion-related acute lung injury and allergic reaction [39] . FFP is also associated with a risk of allergic reactions, such as skin rash, pruritus, urticaria, bronchospasm, angioedema and anaphylactic shock [40] . Studies have shown that infusion of FFP is associated with increased risk and frequency of hospital-acquired infections [41] , and that there is a small potential risk of disease transmission with human plasma [5] . In contrast, PCC manufacture includes at least one step of viral reduction or elimination, which minimises the risk of transmitting infectious agents.
It is discouraging, faced with the potential side-eff ects of FFP, that available data on the effi cacy of FFP are scarce [42, 43] . Several studies comparing the effi cacy of PCCs with human plasma for emergency oral anticoagulant 
Possible means of reducing thrombotic risk
As PCCs were originally designed for the treatment of haemophilia B, their labelling, and thus dosage, is based on the concentration of factor IX. When PCCs are used for VKA reversal, it is important to recognise that warfarin reduces the levels of the vitamin K-dependent coagulation factors to varying degrees, with factor IX remaining at 40 to 50% of normal levels, factor VII at around 30% of normal, prothrombin at 20% of normal and factor X is usually lowest at around 10% of normal [48] . As a result, it is diffi cult to defi ne the optimal ratio of factors in a PCC. Care should be taken, however, to avoid excessive substitution with prothrombin, particularly during repetitive administration of PCCs when prothrombin levels can accumulate because of its long half-life. Co-administration of vitamin K is recommended when PCCs are used for anticoagulation reversal [2] . Vitamin K has a slow onset of action, and the reason for its use is to facilitate hepatic production of coagulation factors after the constituents of the PCC infusion have been metabolised. By reducing the need for repeat administration of PCC, co-adminis tration of vitamin K is one way of reducing thrombotic risk. Although the primary purpose of PCCs is the restoration of coagulation factors, it is also important to consider levels of coagulation inhibitors. VKA therapy reduces levels of protein C, protein S and protein Z as well as the coagulation factors, and the concentration of circulating coagulation inhibitors will be reduced in dilutional coagulopathy. Furthermore, chronic liver disease -which was identifi ed as a risk factor for thrombotic complications in haemophilia patients treated with earlier formulations of PCCs [12] -frequently causes a reduction in the production of antithrombin as well as coagulation factors [49] . To avoid thrombotic complications, monitoring of antithrombin activity and coadministration of antithrombin concentrate should be considered when administering PCCs to patients with severe liver disease [5] . Patients with low levels of endogenous anti thrombin are likely to be at increased risk of thrombosis. Th ere is, therefore, a strong rationale for the inclusion of coagulation inhibitors such as protein C, protein S and protein Z or antithrombin in PCCs [50] .
Accurate bedside monitoring of a patient's coagulation status may provide a means for reducing thrombotic risk.
Conventional coagulation tests such as the prothrombin time are not aff ected by levels of coagulation inhibitors such as protein C; the International Normalised Ratio may therefore not be a true refl ection of the haemostatic state of a patient [31] . During volume replacement of blood loss, particularly with colloids, conventional prothrombin time and activated partial thromboplastin time assays may suggest critical reduction in coagulation factors, whereas the coagulation time measured in whole blood using thrombo elasto graphy may remain within the normal range [51] . Th eoretically, thrombin generation measurement should be preferable for guiding PCC administration and monitoring its effi cacy. Th is analysis is not yet routine in all laboratories, but thromboelastography provides a surrogate estimate of thrombin generation in whole blood [52, 53] .
Ultimately, it is incumbent upon physicians to seek suffi cient restoration of thrombin generation to achieve haemostasis. Normalisation may not be needed and may unmask an underlying predisposition of thrombo embolism. An excessive increase in thrombin generation should thus be avoided. Caution must be exercised, and PCCs are generally not recommended for use in patients at very high risk of thrombosis, such as those with clinical or laboratory evidence of overt DIC.
Conclusions
Th e paradox remains that PCCs are eff ective because they increase the body's ability to generate thrombin, while the total thrombin generation constitutes the primary safety concern with their use. Th e overall capacity to produce thrombin seems to be primarily associated with prothrombin levels. Th e use of PCCs in patients predisposed to thrombogenic complications makes it diffi cult to determine whether thrombogenic events are attributable to or merely coincidental with PCC treatment. Th rombotic risk in patients without underlying risk appears to be fairly low with today's PCCs. Changes to the production of PCCs, designed to address the possible causes of thrombogenic complications, have contributed to their improved safety. Th ese changes include the avoidance of activated factors, greater purity and a well-balanced content of clotting factors and inhibitors. However, additional factors that may contribute to thrombotic complications associated with PCC use remain to be elucidated. Th e putative benefi t of combined administration of PCCs with anti thrombin in high-risk patients such as those with liver insuffi ciency or on VKA therapy is as yet unconfi rmed.
In patients with emergency bleeding, the risk of a thrombotic complication due to treatment with PCCs should be weighed against the need for rapid and eff ective correction of coagulopathy.
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